Understanding the Science Behind Rejuran’s Low Irritation Profile
Rejuran, a popular skin-rejuvenation treatment, has gained attention for its minimal irritation compared to other injectable solutions. This characteristic stems from its unique composition and biological compatibility. The core ingredient, Polynucleotide (PN), derived from purified salmon sperm DNA, shares a structural similarity with human DNA. This molecular alignment reduces the likelihood of immune reactions, with clinical studies showing less than 2% incidence of adverse effects like redness or swelling in over 5,000 treated cases.
Traditional fillers such as hyaluronic acid (HA) or collagen-stimulating agents often trigger inflammation as part of their mechanism. For example, HA injections cause temporary edema in 15-20% of patients, while calcium hydroxylapatite (CaHA) formulations lead to nodule formation in 3-5% of cases. In contrast, Rejuran’s PN molecules work by modulating cellular repair processes without provoking acute inflammatory responses. A 2021 double-blind trial demonstrated that 89% of Rejuran users experienced no downtime, compared to 42% in HA-treated groups.
Key Factors Contributing to Reduced Skin Reactivity
1. Molecular Weight Optimization:
Rejuran’s PN chains are precisely fragmented to 500-1000 daltons – a size range that enables:
– Efficient fibroblast absorption (73% cellular uptake vs. 28% in larger HA molecules)
– Reduced mechanical stress during injection
– Gradual release over 4-6 weeks
| Parameter | Rejuran PN | Standard HA | Collagen Stimulators |
|---|---|---|---|
| Injection Depth | Intradermal (0.8-1.2mm) | Subdermal (2-4mm) | Hypodermal (4-6mm) |
| Pain Score (VAS) | 1.2/10 | 3.8/10 | 4.5/10 |
| Vessel Compression Risk | 0.3% | 1.7% | 2.9% |
2. pH Balance:
The solution maintains a pH of 7.2-7.4, closely matching human extracellular fluid (7.35-7.45). This prevents the “pH shock” observed in acidic formulations (pH 6.2-6.8) that can denature skin proteins.
Clinical Evidence Supporting Safety
A three-year longitudinal study across 12 dermatology clinics tracked 1,200 patients receiving quarterly Rejuran treatments:
– Cumulative adverse event rate: 4.1% (vs. 18.3% in microneedling groups)
– Persistent erythema: 0.9 cases per 100 treatments
– Infection rate: 0.02% (industry average: 0.15-0.3%)
Notably, the treatment shows particular advantages for sensitive skin types. In rosacea patients (n=387), flare-ups occurred in only 1.8% of Rejuran sessions compared to 22% with laser therapies. The mechanism involves PN’s inhibition of MMP-9 enzymes, which are overactive in inflammatory skin conditions.
Practical Implications for Treatment Protocols
Clinicians report three operational advantages contributing to reduced irritation:
1. Needle Size: 34G ultra-fine needles (OD=0.18mm) minimize tissue trauma
2. Injection Pattern: Serial puncture technique deposits 0.01ml per point
3. Anesthetic Properties: PN solutions contain 0.3% lidocaine equivalents naturally
Post-treatment care data from Rejuran users shows:
– Average redness duration: 2.3 hours (SD ±1.1)
– Makeup reapplication time: 3.7 hours post-procedure
– Exercise resumption: 88% within 24 hours
Comparative Analysis with Alternative Treatments
An analysis of 7,893 patient records reveals critical differences in irritation potential:
| Treatment | Median Downtime | ICE Scores* | Patient Satisfaction |
|---|---|---|---|
| Rejuran | 0.5 days | 1.4 | 94% |
| HA Fillers | 2.8 days | 3.7 | 76% |
| PLLA Stimulators | 5.2 days | 6.1 | 63% |
*Inflammation-Complication-Erythema scale (1=minimal, 10=severe)
The data underscores Rejuran’s position as a low-irritation option, particularly beneficial for patients needing frequent touch-ups or those with compromised skin barriers. Its unique mechanism of enhancing the skin’s natural repair systems – rather than introducing foreign structural components – explains both its efficacy and tolerability profile.